BACKGROUND: β-blockers have been among the first medications shown to improve outcomes after acute myocardial infarction (AMI). With the advent of reperfusion therapy and other secondary-prevention medications, their role has become uncertain, and large-scale experience after AMI in the contemporary era is lacking. In particular, the effect of stopping β-blockers in patients initially treated after AMI is unknown.
C
onsiderable progress has been made in the treatment of acute myocardial infarction (AMI) and coronary artery disease in the past 30 years, leading to substantial decrease in early mortality.
1,2 β-Blockers have been among the first classes of medications to document a reduction in early and long-term mortality in patients with AMI. 3 This has led to the highest level of recommendation for their prescription in patients with AMI. 4 By extension, β-blockers are considered first-line therapy for angina relief in chronic coronary artery disease. 5 Most of the trials documenting the efficacy of β-blockers after AMI, however, were performed before the role of reperfusion therapy (fibrinolysis and primary percutaneous coronary intervention [PCI] ) had been demonstrated and before the widespread use of secondary-prevention medications, such as statins or antiplatelet agents.
Because of the lack of evidence from recent randomized trials, the level of recommendation for β-blockers after AMI in patients without left ventricular dysfunction has been downgraded in the most recent European Society of Cardiology guidelines, 6 whereas the American College of Cardiology Foundation/American Heart Association guidelines still strongly recommend β-blockers in all patients with ST-segment-elevation myocardial infarction (STEMI), 7 this divergence reflecting the current uncertainty on their intrinsic usefulness in patients receiving otherwise optimal treatment. 8 Similar discrepancies between guidelines exist for non-STEMI. 9, 10 In addition, the duration of many of the trials assessing the benefit of β-blockers after AMI was short, with few trials having follow-up periods >2 years, 11 and the trials essentially demonstrated the benefits of shortterm β-blocker treatment after AMI. Whether the benefit of β-blockers is confined to the first months after myocardial infarction, or whether protracting β-blocker therapy beyond the first year is also beneficial is a yet unanswered question. Recently, cohort studies have challenged the usefulness of long-term β-blocker therapy in patients with stable (or stabilized) coronary artery disease, 12, 13 whereas others have suggested a benefit in early post-AMI patients, 14, 15 with no impact on outcomes beyond 1 year, 16 leading to interrogations as to the possibility of discontinuing β-blocker therapy in patients with preserved left ventricular function. 17, 18 We, therefore, performed a study to evaluate the impact of β-blocker discontinuation beyond the acute stage in a cohort of patients hospitalized for AMI in 2007 to 2012, who had no evidence of heart failure, were treated optimally (with myocardial revascularization and receiving recommended secondary-prevention medications: combined antiplatelet agents, statins, and angiotensin-converting enzyme inhibitors [ACE-Is] or angiotensin receptor blockers [ARBs]), and who had received β-blocker for at least 1 year after AMI, using the French healthcare databases. For comparison and validation purposes, a similar analysis was performed to assess clinical events after discontinuation of statin therapy.
METHODS

Data Source
The French national health insurance covers the entire French population (65.5 million inhabitants in 2013). Its information system (Système National d'Information Inter-Régimes de l'Assurance Maladie) contains information on each health spending reimbursement, as well as demographic data, such as age, sex, area of residence, or vital status, and is linked to the French hospital discharge database 19 and has been used previously for clinical research, particularly in the field of metabolic and cardiovascular diseases. [20] [21] [22] Hospital discharge diagnoses are recorded using the International Classification of Diseases, Tenth Revision (ICD-10), some codes having been further refined. 17 Patients with severe chronic conditions are entitled to full reimbursement for a long-term disease, which is also recorded as ICD-10 code. The present study was conducted in patients covered by the general scheme of health insurance (75% of the population), with comprehensive data available for the whole period considered. The study was approved by the French data protection agency (Commission Nationale de l'Informatique et des Libertés), but the data access permission policy prohibits making the data set publicly available. All databases used in this study only contained anonymous patient records.
Study Population
All patients admitted to hospital for AMI (ICD-10 code I21-22 with refinement indicating initial management) in 2007
WHAT IS KNOWN
• In the contemporary era of reperfusion therapy and modern secondary-prevention medications, the role of β-blockers in improving outcomes after acute myocardial infarction has become uncertain.
• The effect of stopping β-blockers in patients without heart failure beyond the early phase of myocardial infarction therapy is still being debated.
WHAT THE STUDY ADDS
• The impact of discontinuing β-blockers in patients <80 years, with no recent history of heart failure or acute coronary syndrome, and having received optimal management after acute myocardial infarction was assessed in a large cohort study using the French healthcare databases.
• This study found that discontinuation of β-blockers beyond 1 year after myocardial infarction may increase risk of death or readmission for acute coronary syndrome.
• Statistical significance was not reached for the association with all-cause mortality.
to 2012, aged 25 to 79 years at admission, with myocardial revascularization after AMI, and receiving optimal secondaryprevention therapy, ie, combined β-blocker, statin, ACE-I or ARB, and antiplatelet therapy, were eligible ( Figure 1 ). If there was >1 admission for a given patient during the inclusion period, the index admission was selected randomly. Time was divided into calendar months, month 1 referring to the month after the month of index admission ( Figure I in the Data Supplement). We excluded (1) patients with hospital discharge diagnosis of acute coronary syndrome (ACS; ICD-10 code, I21-I24) in the 2 years before index admission or with hospital discharge or long-term disease diagnosis of heart failure (I50) up to the end of month 4; (2) patients without PCI or coronary artery bypass graft between start of index admission and end of month 4; (3) patients not exposed to each of the following drug classes between months 1 and 4: β-blockers, statins, ACE-Is or ARBs, and antiplatelet agents; and (4) patients having discontinued β-blockers before 1 year.
Exposure
Exposure to β-blockers was modeled as a time-varying variable and in a first step measured on a daily time scale (days covered by the prescription) as described in detail in the Data Supplement. In a second step, exposure was calculated on a monthly time scale: for each month, exposure was recorded if there was at least 1 day of exposure in this month. Finally, β-blocker treatment was considered to be discontinued when there were 4 consecutive months without exposure. Exposures to statins, ACE-Is or ARBs, and antiplatelet agents, respectively, as well as discontinuation of statin treatment were measured in the same way.
Outcome Variables and Follow-Up
Two outcomes were assessed: first, a composite of all-cause mortality or hospital admission for ACS (ICD-10 code for primary or secondary hospital discharge diagnosis, I21-24); and second, all-cause mortality. Time was divided into calendar months. Month m=0 referred to the month of index admission. ACE-I indicates angiotensinconverting enzyme inhibitor; ACS, acute coronary syndrome; AMI, acute myocardial infarction; ARB, angiotensin II receptor blocker; CABG, coronary artery bypass graft; and PCI, percutaneous coronary intervention. *If there was >1 admission for a given patient, the index admission was selected at random. †Four consecutive months without any drug delivery or withdrawal from the general health insurance scheme.
Follow-up started at month 13 (ie, only patients surviving at 12 months were included) and continued until (1) outcome, (2) resumption of β-blocker treatment after discontinuation, (3) loss to follow-up (4 consecutive months without any drug delivery or withdrawal from the general health insurance scheme), (4) month 59 (ie, patients were followed ≤5 years after index admission), or (5) December 2014, whichever occurred first.
Covariates
Baseline covariates included age at index admission, sex, deprivation index, 23 type of index AMI according to ICD codes, drug use in the year before index admission, inpatient treatments between start of the index admission and end of the fourth month after index admission (PCI, coronary artery bypass graft, pacemaker, or cardioverter-defibrillator implantation), as well as the following hospital discharge diagnoses in this period: ischemic stroke, cardiac arrest, ventricular tachycardia, atrial fibrillation, tobacco use, and obesity. In addition, cardiovascular drug use was assessed for the 4 months after index admission (calcium channel blockers, nitrates or other vasodilator agents, other lipid-lowering agents, other antiarrhythmic agents, loop diuretics, other diuretics, and oral anticoagulants).
Time-varying covariates were assessed monthly during follow-up. They covered all the abovementioned inpatient treatments and hospital discharge diagnoses, plus heart failure, as well as use of all the abovementioned cardiovascular drugs, plus statins, ACE-Is or ARBs, and antiplatelet agents. Comorbidities were identified by hospital discharge and longterm disease diagnoses and prescriptions of specific drugs (Data Supplement), consultations with a cardiologist in private practice were searched for, and total length of all hospital admissions for at least 1 night were calculated.
Statistical Analysis
A weighted Cox proportional hazards model (a so-called marginal structural Cox model) was used to estimate the hazard ratio (HR) of β-blocker discontinuation versus continuation, controlling for baseline and time-varying confounding. [24] [25] [26] Each patient's contribution to the risk set for a given month t was weighted by the inverse of the probability of the treatment history he/she actually had, given his/her covariate history. To correct also for potentially informative censoring at treatment resumption, the patient's initial weight was multiplied by the inverse probability of remaining uncensored up to month t, given his/her covariate history. The resulting weights are called inverse probability of treatment and censoring weights. Details, including information on weight truncation, are provided in Figure II in the Data Supplement. All baseline and time-varying covariates listed in Tables 1 and 2 were used for weight calculation, plus the calendar year of index admission. Using the same weights, the inverse probability of treatment and censoring weights method was also applied to calculate adjusted cumulative incidence curves. 26 Their 95% confidence bands were obtained by bootstrap with 200 replications.
Predefined subgroup analyses were performed, according to sex, prior use of β-blockers before index admission, type of myocardial infarction, presence of asthma or chronic obstructive pulmonary disease at baseline, and type of β-blockers: vasodilating β-blockers (carvedilol, nebivolol, labetalol et celiprolol) and conventional β-blockers (others). Data are expressed as n (%) unless otherwise indicated. ACE-I indicates angiotensin-converting enzyme inhibitor; AMI, acute myocardial infarction; ARB, angiotensin II receptor blocker; CABG, coronary artery bypass graft; and MI, myocardial infarction.
*Subsequent MI was grouped together with transmural MI. †Data refer to the period between the start of the index admission and the end of the fourth month after index admission.
Sensitivity analyses focused on the impact of weight truncation and the role of the different time-varying covariates in adjustment. In a first complementary analysis, a conventional multivariate Cox analysis was performed, including all baseline and time-varying covariates listed in Tables 1 and 2 , plus the year of index admission. In a second complementary analysis, patients were not censored when they resumed the treatment after discontinuation, but they were continued to Data are expressed as n (%) unless otherwise indicated. ACE-I indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; and LTD, long-term disease (entitled to full reimbursement).
*Data refer to patients present in the study at the end of the considered 4-mo period. Recall that follow-up started at month 13 and did not exceed month 59 and that follow-up was stopped at resumption of β-blocker treatment (after discontinuation). †These comorbidities were identified by hospital discharge and LTD diagnoses or prescriptions for specific drugs. ‡In private practice or private clinic. §For β-blockers, statins, ACE-Is or ARBs, and antiplatelet agents, exposure was determined as indicated in the text, whereas for the other drugs, the presence of at least 1 filled prescription was tested.
be considered as having discontinued treatment, and estimation was based on inverse probability of treatment weights only (no censoring weights).
Reported P values are 2 sided, and results were considered statistically significant for P<0.05. All statistical analyses were performed with SAS software, version 9.2 (SAS Institute, Inc, Cary, NC). The SAS program was based on codes published previously. 24, 26 
RESULTS
A total of 73 450 patients were included in the study (Figure 1 ). Mean duration from index admission to end of follow-up was 3.8 years (range, 13-59 months). Baseline and time-varying characteristics are summarized in Tables 1 and 2 . A total of 4381 patients died or were admitted for ACS, corresponding to a crude incidence rate of 2.1 per 100 patient-years. For death, the number of events was 2739, corresponding to a crude incidence rate of 1.3 per 100 patient-years.
β-Blocker Exposure and Predictors of Discontinuation
Total follow-up time was 2 455 104 patient-months, of which 144 024 (5.9%) were time with discontinued β-blocker treatment.
The β-blockers prescribed during follow-up were predominantly cardioselective (95.9% of the total number of pills). Bisoprolol was the most commonly prescribed (46.7%), followed by atenolol (20.4%), acebutolol (14.4%), nebivolol (8.3%), metoprolol (5.2%), carvedilol (1.8%), sotalol (1.7%), and celiprolol (0.7%).
The most important factors related with β-blocker discontinuation were time varying: use of calcium channel blockers (adjusted odds ratio [OR], 2.4; 95% confidence interval, 2.3-2.6) and other antiarrhythmic agents (adjusted OR, 1.8; 95% confidence interval, 1.6-2.1), as well as a pacemaker implantation (adjusted OR, 1.8; 95% confidence interval, 1.2-2.8) and a prolonged total length of hospital admissions; conversely, time-varying exposure to statins (adjusted OR, 0.30; 95% confidence interval, 0.28-0.32), ACE-Is or ARBs (adjusted OR, 0.49; 95% confidence interval, 0.46-0.52), and antiplatelet agents (adjusted OR, 0.29; 95% confidence interval, 0.25-0.34), cardiodefibrillator implantation (adjusted OR, 0.44; 95% confidence interval, 0.21-0.93), and coronary artery bypass graft (adjusted OR, 0.53; 95% confidence interval, 0.34-0.82), as well as β-blocker use in the year before index admission (adjusted OR, 0.54; 95% confidence interval, 0.51-0.58) were associated with a lower likelihood of discontinuation. The estimated exposure model is fully described in Table 3 , as well as the estimated model of treatment resumption. The same analyses were performed for statin therapy (Table  I in the Data Supplement).
Among the 10 409 patients who discontinued β-blocker treatment, 4432 (42.6%) resumed treatment during follow-up. Among these 4432 patients, 1647 (37.2%) resumed in the first month after the 4-month period without exposure, 816 (18.4%) in the second month, and 487 (11.0%) in the third month.
Clinical Events After β-Blocker Discontinuation
The crude HR for death or ACS, comparing β-blocker discontinuation versus continuation, was 1.22 (95% confidence interval, 1.09-1.37), whereas the adjusted HR was 1.17 (95% confidence interval, 1.01-1.35). The adjusted cumulative incidence rate of the composite outcome event at month 59 (ie, 5 years after index admission) was 9.4% (95% confidence interval, 8.4%-10.4%) for β-blocker discontinuation versus 8.0% (95% confidence interval, 7.7%-8.3%) for continuation ( Figure III in the Data Supplement). The crude and adjusted HR for death were 1.24 (95% confidence interval, 1.08-1.44) and 1.13 (95% confidence interval, 0.94-1.36), respectively.
Subgroup analyses for the composite outcome showed no important effect modification according to sex or previous use of β-blockers before the index episode, but the estimated effect of β-blockers discontinuation was modified by the type of AMI (no effect in patients with nontransmural AMI, or transmural AMI not located to the anterior or inferior walls) and the presence of asthma/chronic obstructive pulmonary disease at baseline (statistical significance was not reached in patients without asthma/chronic obstructive pulmonary disease at baseline; Figure 2 ). The adjusted HR for death or ACS was 1.07 (95% confidence interval, 0.77-1.49) for vasodilating β-blockers and 1.16 (95% confidence interval, 0.99-1.37) for conventional β-blockers.
Sensitivity and Complementary Analyses
The results were not sensitive to the thresholds used for weight truncation (Table II in the Data Supplement): for the composite outcome, truncation at the 0.1% and 99.9% percentiles resulted in an HR of 1.16 (95% confidence interval, 0.99-1.36), whereas truncation at the 1% and 99% percentiles yielded an HR of 1.18 (95% confidence interval, 1.03-1.35). Beside exposure to statins, to ACE-Is or ARBs, and to antiplatelet agents, the covariates with the most important impact on adjustment were consultation with a cardiologist, prolonged total length of hospital admissions, and calcium channel blocker use (Table III in 
Comparative Analysis of Clinical Events After Statin Discontinuation
The study's approach was also applied to statin exposure, considering patients not having discontinued statins before 1 year and yielded an adjusted HR of 2.31 (95% confidence interval, 2.01-2.65) for the composite outcome and 2.57 (95% confidence interval, 2.19-3.02) for all-cause mortality ( Figure 
DISCUSSION
In patients <80 years of age with AMI, no evidence of heart failure or ACS in the previous 2 years, and receiving optimal medical and revascularization therapy, stopping β-blockers beyond 1 year after the acute episode was associated with an increased risk of a composite outcome of death or readmission for ACS and was not significantly associated with increased all-cause mortality. The increased risk was not found in patients with nontransmural myocardial infarction, and it was not statistically significant in patients without asthma/chronic obstructive pulmonary disease at baseline. The sensitivity analyses showed consistent results. These findings sharply contrasted with the observation of a >2-fold increase in risk of events after stopping statin therapy.
Rate of β-Blocker Discontinuation
The rate of discontinuation of β-blockers was low (14.2% of all patients, 9.5% among all patients still present at month 59). An additional 5.4% who had received β-blockers during the first 4 months had stopped their treatment during the first year and were, therefore, excluded from the study. Large variations in adherence to β-blockers have been reported, depending on the population selected, clinical context, country, health insurance coverage, and way adherence was assessed (proportion of days covered versus discontinuation). Thus, in a large UK database in primary care, Kalra et al 27 found that β-blocker discontinuation increased from 27% at 1 year to 50% at 3 years; the population, however, included patients with heart failure or angina, in addition to patients with myocardial Coefficients related to time trend were omitted from the table (time trend was decreasing for β-blocker discontinuation). Conservative CIs were derived using robust standard errors adjusting for within-patient clustering. AUC was 0.692 for the model of discontinuation and 0.697 for the model of resumption. ACE-I indicates angiotensin-converting enzyme inhibitor; AMI, acute myocardial infarction; ARB, angiotensin II receptor blocker; AUC, area under curve; CABG, coronary artery bypass graft; CI, confidence interval; COPD, chronic obstructive pulmonary disease; LTD, long-term disease (entitled to full reimbursement); MI, acute myocardial infarction; and OR, odds ratio.
*Among the patients not having discontinued before month m. Recall that discontinuation of β-blockers at month m was defined by the absence of exposure during the months m-3 to m (as first 4-mo period without exposure since index admission).
†Among the patients having discontinued before month m. ‡Subsequent MI was grouped together with transmural MI. §Data refer to the period between the start of the index admission and the end of the fourth month after index admission. ‖Discontinuation model: cardiovascular drug use assessed in months m-3 to m-1, other covariates in months m-7 and m-4; resumption model: all covariates assessed in months m-3 to m.
¶These comorbidities were identified on hospital discharge and LTD diagnoses or prescriptions for specific drugs. #In private practice or private clinic. **For statins, ACE-Is or ARBs, and antiplatelet agents, exposure was determined as indicated in the text, whereas for the other drugs, the presence of at least 1 filled prescription was tested. infarction. In a large cohort of patients hospitalized for AMI in 2001 in the United States, 35% of the patients with β-blockers at 30 days were poorly adherent at 1 year. 28 A similar figure (27%) was observed in a large population of elderly patients with post-AMI in Ontario, but the proportion of patients with very low adherence rates (<40% of days covered) was only 9%. 29 Our figure for discontinuation of β-blockers compares with data from the Canadian Acute Coronary Syndromes Registry II, 30 which documented a discontinuation rate of 10% between discharge and 1 year for β-blockers, and with those of a survey in Switzerland, in which 9.5% of patients on β-blockers after AMI had stopped their treatment at 1 year. 31 Likewise, in the 2005 FAST-MI, 11% of the patients with β-blockers at discharge had stopped their medication at 1 year. 16 In fact, beyond the potential role of health insurance coverage in France (all secondary-prevention medications after AMI being fully reimbursed), the low discontinuation rate in our population is also likely explained by the selection criteria we used: patients with myocardial revascularization at the acute stage, receiving full optimal therapy at discharge and in the months immediately following, and <80 years of age.
Prognostic Impact of β-Blockers in the Era of Reperfusion Therapy and Other Evidence-Based Therapies
Most of the trials documenting the benefit of β-blockers have been performed before the era of reperfusion therapy and the benefit was observed in high-risk subgroups. 32 In a recent meta-analysis of β-blocker trials in AMI, Bangalore et al 11 found that β-blockers reduced mortality and improved outcomes in the prereperfusion era but had no such effect in the most recent period. The results with β-blockers in the most recent period, however, were mostly driven by those of the COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial), 33 in which 45% of the patients had no reperfusion therapy and none were treated with primary PCI; also, the primary outcome of the trial was at 28 days.
Several observational studies have assessed the relationship between β-blocker prescription, adherence or discontinuation after AMI, and clinical outcomes. Twenty years ago, in 1994 to 1995, the Cooperative Cardiovascular Project showed that prescription of β-blockers at discharge was associated with improved survival, particularly in high-risk groups, and in patients with nontransmural infarction; at that time, statins were virtually not used, and primary PCI was uncommon. 34 The GRACE showed that early (≤24 hours from admission) treatment with β-blockers in patients with non-STEMI included from 1999 to 2004 was associated with lower hospital and 6-month mortality, but no information beyond that time is available. 35 More recently, in a Korean registry of patients admitted between 2004 and 2009, β-blocker prescription at discharge was associated with lower mortality at 3 years. 15 A dose-responsetype adherence-mortality association was observed for β-blockers in 31 455 elderly AMI survivors included between 1999 and 2003 from the Ontario reimbursement database. 13 A more pronounced association was observed with statin therapy. In the PREMIER Registry, 36 early discontinuation of β-blockers (1 month after AMI) was associated with a 2-fold increase in mortality at 1 year (adjusted HR, 1.96; 95% confidence interval, 1.10-3.45). Conversely, the large REACH Registry, assessing outcomes of 14 043 patients with previous myocardial infarction during 44 months of follow-up, showed no significant impact of late discontinuation of β-blockers.
12
In patients with a recent AMI (in the past year), the risk of cardiovascular death, myocardial infarction, or stroke was numerically lower with β-blocker therapy (HR, 0.79; 95% confidence interval, 0.60-1.04), with a significantly reduced risk of cardiovascular events, including Tables 1 and 2 , plus the year of index acute myocardial infarction (AMI). CI indicates confidence interval; and COPD, chronic obstructive pulmonary disease.
hospitalization or revascularization (HR, 0.77; 95% confidence interval, 0.64-0.92).
Recently, the FAST-MI 2005 registry found that persistence with β-blockers therapy during the first year was not associated with higher 5-year mortality (adjusted HR, 1.19; 95% confidence interval, 0.65-2.18). 16 However, the latter analysis was based on a relatively small number of patients (after propensity score matching, 95 patients without β-blockers were compared with 277 patients with β-blockers). Finally, a recent study based on 90 869 Medicare beneficiaries of ≥65 years of age, who survived >180 days after AMI hospitalization in 2008 to 2010 and followed ≤18 months, suggested limited additional benefit for β-blockers in patients who were adherent to statins and ACE inhibitors/ARBs. 37 Also, better clinical outcomes were observed with vasodilating β-blockers than conventional β-blocker therapy in patients with AMI based on multicenter Korean Acute Myocardial Infarction Registry data. 38 Direct comparisons with these studies are difficult because of methodological issues, including important differences concerning the definition of study populations, healthcare setting, design, and length of followup. However, overall, these data suggest a benefit of β-blockers, particularly in the early phase of therapy and in high-risk patients, with smaller or even absent effect beyond 1 year.
The results from our large-scale cohort study are in keeping with a potential benefit of β-blockers beyond 1 year of the AMI, albeit clearly less pronounced than that of statin therapy: the adjusted HRs of β-blocker discontinuation versus continuation were 1.17 (95% confidence interval, 1.01-1.35) and 1.13 (95% confidence interval, 0.94-1.36) for the composite outcome of death or readmission for ACS and for all-cause death, respectively.
Strengths and Limitations
Observational studies with time-varying exposure are particularly challenging, both with respect to the study design and the analytical method. The use of marginal structural models is a major strength of our study because they can appropriately correct for timevarying confounders affected by previous exposure and for informative censoring. This is not the case for conventional multivariate Cox models which, in particular, remove indirect effects mediated by these confounders, and it is, therefore, not surprising that the 2 approaches resulted in somewhat different effect estimates (for the composite outcome, the conventional model yielded an HR of 1.09). Marginal structural models are being increasingly applied in pharmacoepidemiologic studies, 39 including studies on β-blockers and statins. 40, 41 However, they rely on the assumption of no unmeasured confounding-an assumption we discuss below.
With our study design, time-related bias, in particular immortal time bias, was avoided by (1) defining the study population based on information on a fixed time period (up to month 12 after index admission) and starting follow-up at a time point after this fixed time period (month 13), and (2) using a time-dependent exposure variable whose value at month m is defined by information up to m-1. 42, 43 Prevalent users may be a concern in study design. 44 For the population, we studied prevalent user bias is per se limited because prior users and nonusers experienced AMI, and both were treated by β-blockers after AMI. Moreover, only less than one quarter of the patients had received β-blockers before the index episode, and subgroup analyses showed that the estimated effect of β-blocker discontinuation differed only slightly between prevalent users (HR, 1.14; 95% confidence interval, 0.87-1.51) and new users (HR, 1.20; 95% confidence interval, 1.02-1.42).
This real-life study experiences some fundamental limitations common to observational studies using healthcare databases. First, treatment was defined by the prescriptions filled-in, and we cannot formally exclude that some patients may have bought the medications but not actually taken them; such a bias would result in an underestimated difference between treatment discontinuation and treatment continuation. The dose of β-blockers could not be documented, and, therefore, we have no means to determine whether the patients still on β-blockers received an optimal dose; use of suboptimal doses might have attenuated the between-group difference; conversely, however, our study reflected the use of β-blockers, such as observed in real life. Second, detailed medical or psychosocial characterization of the patients is limited; thus, we could not separate between STEMI and non-STEMI because the ICD-10 classification only classifies infarctions into transmural and nontransmural infarctions; also, left ventricular ejection fraction was not available. In this regard, it is noteworthy that bisoprolol-a medication preferentially used in patients with left ventricular dysfunction-was the most widely used β-blocker; however, if some patients with poor left ventricular function were in fact included in our cohort, the bias thus created would tend to favor the efficacy of β-blockers and not the reverse. Third, the precise reasons for β-blockers or statins discontinuation were unknown. However, important cardiovascular risk factors, cardiovascular drug use, and comorbidities were searched for both at baseline and continuously during follow-up, and their association with treatment discontinuation was taken into account by the chosen analytical method. Of note, some risk factors increased the probability of β-blocker discontinuation, for example, male sex, whereas others decreased it, for example, obesity, diabetes mellitus, and cancer. For statin discontinuation, the direction of some associations was reversed, for example, diabetes mellitus and cancer increased the probability of statin discontinuation, whereas male sex decreased it. Because of the observational nature of our study, however, residual confounding cannot be excluded. Adherence is a complex human behavior influenced by environmental and other factors only partially measured in medico-administrative databases, and some of these factors may be associated with death or untoward clinical events. In particular, only a minority of the patients (14.2% of patients and 5.9% of patientmonths) stopped their β-blocker treatment, suggesting that this population may have specificities and some of them may not have been captured in our databases. Statin discontinuation was still rarer than β-blocker discontinuation (10.4% of patients and 3.1% of patientmonths). Residual confounding might, therefore, explain why the benefit observed in our analyses of statin therapy was larger than expected: continuation of statin therapy was associated with a >50% reduction in events (including mortality) compared with statin discontinuation-a magnitude of effect much greater than findings in randomized statin trials after myocardial infarction (≈20% reduction in events). 45, 46 However, the comparison of the potential bias in the analyses of β-blockers and statins should be made with caution.
Finally, treatment discontinuation was defined as at least 4 consecutive months without exposure, and we, therefore, could not measure a potential short-term deleterious impact of β-blocker discontinuation. Because the follow-up of patients began 1 year after index AMI, the results of our study cannot be generalized to this first year.
Conclusions
The results of this study based on medico-administrative data suggest a potential benefit associated with maintaining β-blocker therapy beyond 1 year after AMI in patients <80 years, with no recent history of heart failure or ACS, and receiving optimal management, including both myocardial revascularization and all recommended secondary-prevention medications at the acute stage. However, unmeasured confounding might explain this result in light of the overestimated benefit of statin therapy, found in this study using a similar methodology, compared with that reported in randomized trials. Pending the results of contemporary randomized clinical trials assessing the role of β-blockers in this setting, observational studies from multiple sources, when carefully designed and analyzed, can provide useful information and contribute, together, to update guidelines on the use of β-blockers therapy after AMI.
